(Teleborsa) - Weak sitting in Piazza Affari for Philogen, an Italian-Swiss biotechnology company listed on Euronext Milan, despite Goldman Sachs has increased the target price to 21 euros per share from...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
(Teleborsa) - Weak sitting in Piazza Affari for Philogen, an Italian-Swiss biotechnology company listed on Euronext Milan, despite Goldman Sachs has increased the target price to 21 euros per share from...